Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

B. Green, Jennifer; Angelyn Bethel, M.; W. Armstrong, Paul; B. Buse, John; S. Engel, Samuel; Garg, Jyotsna; Josse, Robert; D. Kaufman, Keith; Koglin, Joerg; Korn, Scott; M. Lachin, John; K. McGuire, Darren; Pencina, Michael; Standl, Eberhard; P. Stein, Peter; Suryawanshi, Shailaja; Van de Werf, Frans; D. Peterson, Eric; R. Holman, Rury

doi:10.1056/nejmoa1501352

Public

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Published in New England Journal of Medicine • Jun 8, 2015

Authors:

Jennifer B. Green

M. Angelyn Bethel

Paul W. Armstrong

Abstract

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add eith...

Subject

Sitagliptin

Medicine

Semaglutide

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!